Fatty livers are susceptible to factors that cause inflammation and fibrosis, but fat deposition and the inflammatory response can be dissociated. While nonalcoholic fatty liver disease (NAFLD), caused by pathologic fat accumulation inside the liver, can remain stable for several years, in other cases NAFLD progresses to nonalcoholic steatohepatitis (NASH), which is characterized by fat accumulation and inflammation and is not a benign condition. In this review, we discuss the NASH host cells and microbial mechanisms that stimulate inflammation and predispose the liver to hepatocyte injury and fibrotic stages via increased lipid deposition. We highlight the interactions between intestine-derived bacterial products, such as lipopolysaccharide, and nutritional models of NAFLD and/or obese individuals. The results of modulating enteric microbiota suggest that gutderived endotoxins may be essential determinants of fibrotic progression and regression in NASH.
Introduction
Nonalcoholic fatty liver disease (NAFLD), described by pathologic fat accumulation inside the liver, is well characterized. However, hepatocyte injury involved in the progression of NAFLD to nonalcoholic steatohepatitis (NASH), and particularly the inflammatory and profibrotic drivers of NASH, need further clarification. Evidence shows that pro-inflammatory stimuli, such as oxidative stress and mitochondrial dysfunction, determine the evolution of NASH [1] [2] [3] . But whether targeting lipotoxicity-mediated activation of immune cells is useful for the prevention or treatment of NASH remains unclear. Recently, new approaches using inhibition of fibrogenesis, and reversal of advanced fibrosis and cirrhosis, demonstrate that secretion of endotoxins originating from the gastrointestinal (GI) tract can play important roles in this process [4] . Bacterial products provoke the release of pro-inflammatory mediators, such as chemokines, cytokines, and reactive oxygen/nitrogen species, which contribute to deleterious effects involving inflammatory infiltration and fibrosis in the liver [5, 6] . While gut microbiota are associated with different phenotypes of NAFLD in the liver where the more serious NAFLD lesions are linked with gut dysbiosis [7] , many studies indicate that it is important to examine the contribution of the gut-liver axis to the pathogenesis of chronic liver diseases (Fig. 1) . Here, we discuss the important roles of gut microbiota in pathogenesis of NASH and progression of liver disease.
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Dysbiosis and progression of chronic liver injury
The liver is the main target of bacterial products derived from the intestine. Bacterial translocation augments liver injury [8] [9] [10] , which proposes that the liver-gut axis plays a role in the pathogenesis of NASH. Studies using animal models indicate that gut-derived endotoxins mediate the development of NASH, while treatment with probiotics prevents histological alterations and insulin resistance (IR) associated with steatohepatitis [11, 12] . Detoxification from intestinederived toxins elevates liver exposure to these substances; this occurs via activated macrophages, which release hepatotoxic factors by means of abnormal activation of the immune system [13] . However, studies conducted with human patients indicate that the exact mechanisms remain unclear [14, 15] .
Small intestinal bacterial overgrowth
Changes or imbalance in gut microbiota may be a primordial contributing factor that influences the onset of liver dysfunction via inflammation and development of fibrosis [16] [17] [18] [19] [20] [21] [22] . An imbalance of microbiota in the intestine can have serious consequences, including small intestinal bacterial overgrowth (SIBO). SIBO involves the translocation of colonic bacteria into the small intestine, which triggers disruption of intestinal homeostasis and decreased mobility of small intestine, leading to increased intestinal permeability and endotoxin absorption [23] . SIBO occurs with higher incidence in patients with NASH [24] , and is accompanied by elevated concentrations of interleukin and disrupted metabolic activity of intestinal microbiota [25] . Therefore, impaired intestinal motility may contribute to the Fig. 1 . Involvement of the gut-liver axis in the pathogenesis of NAFLD/NASH progression. Articles were selected based on a PubMed search (http://www.ncbi.nlm. nih.gov/pubmed/) using the terms "microbiota," "LPS," "NASH," and "NAFLD" from 1997 to 2017; the search was limited to articles written in English. Articles were selected based on general review of the literature. If an article contained a reference that had not been detected in the search or general reading, this reference was obtained. A, Reviews5, 6, 8, 9, 13, [17] [18] [19] [20] [21] [22] 26, 29, 31, 32, 35, 36, 38, 47, 54, 56, 57, 67, 90, 91, 94, 97, 100, 103, 106, 107, 125, 138 
Intestinal permeability and endotoxins
While changes in gut microbiota can independently indicate the severity of NAFLD [27] , increased permeability is also involved via rupture of intercellular junctions. This may be an essential factor in intestinalbarrier function [28] . Analysis of intact narrow junctions in the intestine, which prevent alterations in the intestinal flora, shows that a delicate balance is necessary to maintain intestinal functionality and to avoid immune responses against invading commensal microbes [29] . Changes in the function of intestinal tight-junction protein occludin play a major role in increased intestinal permeability. Thus, impairment of tight junctions increases intestinal permeability, which is accompanied by the translocation of microbial products from intestinal lumen to the bloodstream [30, 31] . Modulators of this new gut vascular barrier are not yet determined; however, dietary factors, mucosal inflammation of any etiology (such as that involving drugs, infections, or toxins), and hypoperfusion, are currently recognized as disruptors of the intestinal epithelial wall [32] .
Endotoxemia, LPS, and toll-like receptors
Excess levels of endotoxins, which can reach the liver through portal circulation, result from higher concentrations of endotoxins in the gut due to bacterial overgrowth, or from increased absorption of endotoxin from the gut in patients with NASH [33] . Particularly, fatty liver is severely damaged when lipopolysaccharide (LPS) from the Gram-negative intestinal microflora is present after bacterial death. The damage occurs via pattern recognition receptors, including Toll-like receptors (TLRs), when the innate immune system identifies conserved pathogen-associated molecular patterns (PAMPs) [34] . Whereas a healthy liver expresses low mRNA levels of TLRs, which results in elevated hepatic resistance to TLR ligands from the intestinal microbiome [35, 36] , TLR4, responsive to LPS, is expressed by Kupffer cell (KC), hepatic stellate cell (HSC), hepatocytes, biliary epithelial cells, sinusoidal endothelial cells, and hepatic dendritic cells [37] . LPS, transported via TLR4-dependent pathway, can play an important function for patients with NASH who have previous history of benign steatosis [38, 39] . In fact, several studies have investigated how to counteract and reverse the pro-inflammatory and lipogenic effects of LPS [40] [41] [42] [43] [44] [45] . These data imply that liver damage can occur when hepatic immune cells are exposed to TLR ligands [46] [47] [48] . Studies have also confirmed the significance of TLR4 upregulation in the liver and intestine-derived LPS in experimental models of NASH (Fig. 2) . Consequently, TLRs can be viewed as key receptors regulating inflammation, increased activity of myofibroblasts. LPS-mediated TLR4 activation plays a role in fibrogenic signaling pathways [49, 50] . Specifically, hepatocyte-specific deletion of myeloid differentiation primary-response gene 88 (Myd88), which is a common TLR signaling adaptor, leads to liver inflammation, steatosis, and IR [51] , and KCs positive for cluster of differentiation 14 (CD14) shows an enhanced response to stimulation with low-dose LPS in simple steatosis [52] . Hence, LPS-induced intestinal permeability is related to TLR4-dependent increases via CD14 expression [53] [54] [55] . This important regulatory factor in LPS-induced inflammation enhances the effects of LPS, leading to the development of NAFLD/NASH, and can modulate metabolic activity, stimulating production of pro-inflammatory factors [56] [57] [58] .
Increased sensitivity to endotoxin-induced injury in model of NASH
A methionine/choline-deficient (MCD) diet, widely utilized like an animal model of NASH, enhances susceptibility to the TLR4 ligand LPS [59] . Achiwa et al. [60] showed in mice lower colon length, increased incidence of mucosal changes in the ileum and colon, inflammation and, hepatic fibrosis for choline-fat-deficient diet (CDHF) linked with higher LPS concentrations in the CDHF group plus a dextran sodium sulfate (DSS)-induced colitis model. Similarly, Gabele et al. [61] have shown that combining high-fat (HF) diet and DSS leads to disrupted homeostasis between gut microbiota and the host organism. This suggests that bacterial translocation from the gut into portal circulation leads to liver damage, indicating that gut microbiota is highly involved in NAFLD and obesity. Endotoxemia causes elevated levels of tumor necrosis factor alpha (TNF-α) in steatohepatitis [11, [62] [63] [64] , and these findings indicate innate immune reactivity in the cells of patients with NASH [65] . However, Kirsch et al. [66] observed that while an MCD diet increases the levels of LPS, TNF-α does not appear necessary for the development of steatohepatitis. Therefore, alternative cytokines may participate of roles normally played by TNF-α, and further studies are necessary to delineate the exact cytokine response in TNF-α-knockout animal models.
Hepatic fat accumulation, gut derived factors, and NASH progression
Nutrient consumption is a vital factor in the evolution of NASH [67] . Alterations in the composition of intestinal barrier function are associated with development of steatosis and progression of NASH [68] , while an augmented response to accumulation of hepatic fat is observed with NASH models using diet and gut-derived factors (Table 1) . Choline, for example, is implicated in levels of low-density lipoprotein and dysfunction of hepatic lipid export [69] . In that way, microbiota promotes hepatic steatosis, IR, and injury via lipoperoxidation. In particular, there are interactions between choline deficiency diet and dysfunction of the GI microbiome [70] . In this model, the inflammatory response, stimulated either by LPS or by pro-inflammatory intermediates, can be efficiently counteracted by peroxisome proliferatoractivated receptor alpha-mediated transrepression of signaling pathways that involve adipose triglyceride lipase [71, 72] . As a result, MCD diet and LPS causes steatohepatitis with enhanced role of hepatic proinflammatory mediators [73, 74] .
In rodents, a high-cholesterol (HC) diet, used to model steatohepatitis including an IR phenotype that closely resembles human NASH, aggravates the sensitivity to LPS and TNF-α [74] . KCs of HF-fed rats secrete pro-inflammatory cytokines and chemokines under LPS stimulation and can be reversed by inhibition of lipogenesis [75] . Infusion of LPS causes hepatic steatosis, triggering gain of liver and adipose tissue weight, liver IR, and glycemia/insulinemia, which are characteristics comparable to those obtained via HF diet. However, this did not occur in CD14 mutant mice [76] , demonstrating that CD14/TLR4 signaling is essential for metabolic diseases that are induced by LPS. Moreover, while specific knockout models also show improvements in metabolic phenotypes upon administration of HF diet, the TLR5-knockout model exhibits a contradictory phenotype, with increased body weight, steatosis, and blood glucose defending against gut bacteria and diet-induced liver injury [77] .
The intestinal epithelium, along with its colonizing bacteria, characterizes an initial point of connections between diet and the host immune system associated with the development of liver disease [78] . This interaction can impact the structure and composition of intestinal microbiota in which fatty liver alters bacterial capacity for energy harvest [79] [80] [81] [82] . Although an HF diet alone causes a steatotic liver without NASH or inflammation within 10 wk of treatment [83] , a HF diet for 16 weeks show markedly altered intestinal microbiota and intrahepatic cytokine profiles [84] . Similarly, a synthetic diet of HF and sucrose, administered for 5 wk and combined with stimulation by LPS, causes mild steatosis of liver cells in rats, leading to a high sensitivity of the liver to harmful factors [85] . Fukunishi et al. [86] also showed that LPS aggravate steatosis, focal necrosis, and fibrosis in the livers of Zucker rats when used twelve weeks of exposure to this synthetic diet and LPS treatment in the last 2 weeks. However, consumption of fructose with controlled caloric intake generates signs of endotoxemia and liver damage without evident modification in the microbiome [87] .
This finding indicates that although fructose-induced intestinal dysbiosis can only occur in the presence of excess energy consumption, liver damage is not always connected to the microbiome.
Lipid accumulation is linked to a fibrotic KC phenotype, which is accompanied by increased release of several cytokines and chemokines, resulting in NASH [43, 88] . However, fibrogenesis is dependent on TLR4 expression in HSCs more than that in other hepatic cell types, as demonstrated by experiments in chimeric mice [89] . TLR4 was shown to mediate HSC activation through increased exposure to KC-derived transforming growth factor (TGF-β). This response was observed with HSC-mediated KC chemotaxis, where HSC activation and fibrogenesis were nearly completely suppressed in KC-depleted mice. This view is supported by endotoxin signaling identified in HSCs activation (Table 2) , while fibrogenic cell type in injured liver mediates key responses and inflammatory phenotype [90, 91] . In-vitro models can offer mechanistic insights into how inflammation and lipotoxicity directly contribute to the development of NASH [92] . Tang et al. [93] investigated the importance of LPS-induced liver injury in administration of HF diet. IL-17, which mediates potent inflammatory immune responses, also causes accumulation of intracellular lipids [93] . This may play a crucial role in inflammation of NAFLD and may favor hepatic steatosis and a pro-inflammatory response in NAFLD, facilitating the transition from simple steatosis to steatohepatitis. Moreover, nucleotide oligomerization domains (NOD)-like receptors (NLRs) have been found to play a major role in NASH pathogenesis. NLR activation in response to injury, coupled with damage-associated molecular pattern molecules (DAMPs) or PAMPs, mediates the recruitment of the inflammasome, a multiprotein complex required for caspase-1 activity and initiation of inflammatory signals [94] . Nucleotide-binding domain leucine-rich repeat protein (NLRP)6 and NLRP3 inflammasomes are sensors of endogenous or exogenous PAMPs or DAMPs, and negatively control the development of NAFLD and NASH by modulating gut microbiota [95] . This suggests that dysbiosis alone can stimulate steatosis and metabolic syndrome, as demonstrated by Csak et al. [96] .
The influence of gut microbiota on energy metabolism in the liver may also be mediated by short-chain fatty acids (SCFAs) including acetate (C2), propionate (C3), and butyrate (C4). SCFAs are the major metabolic products of bacterial anaerobic fermentation in the intestine. SCFAs constitute a substantial portion of essential energy, which favors the development of steatosis, increasing the distribution of SCFAs to the liver [97] . However, SFCAs also act on other cells to regulate various leukocyte roles [98] connected with G protein-coupled receptor 43 (GPR43), which affects inflammatory responses. Gpr43 −/− mice show systemic inflammation in various tissues [99] . Acetate can reduce liver damage induced by bacterial products. This beneficial effect of acetate is not observed in GPR43 -/-mice when SCFA/GPR43 signaling increases intestinal permeability [100] . Furthermore, bacteria inside the intestine can also chemically transform bile acids, thereby altering composition of bile-acid pool. While bile acids play a role as detergents to enable fat absorption, they are now documented as vital cell-signaling molecules activating several pathways [101] . Bile acids in the intestine act as strong anti-microbial agents controlling the growth of gut bacteria and microbiome composition. Bile acid molecules exert these effects by binding and activating farnesoid X receptor (FXR; nuclear hormone receptor) and G protein coupled cell surface receptor TGR5 [102, 103] . FXR knockout mice receiving HF diet showed some aspects of NASH, such as hepatic steatosis and necroinflammation [104] ; as well as administration of TGR5/FXR agonists alleviate NAFLD and diminish inflammation in the liver [105] .
Antibiotics, probiotics, and prebiotics in liver disease/NASH studies
Microbiota manipulation can be considered a potentially effective therapeutic option for the treatment of NAFLD/NASH. Understanding how microbiota influences liver disease is vital in the treatment and prevention of complications such as cirrhosis, with emerging data supporting the role of antimicrobial intervention [106] [107] [108] . Numerous studies demonstrate the relationship between gut microbiota and liver diseases (Table 3) , which raises the possibility of normalizing gut microbiota as a therapeutic strategy.
Rationale for use of antibiotics in patients and animal models with chronic liver disease
In patients with bacterial peritonitis, treatment with antibiotics is correlated with diminished bacterial translocation [109] . LPS levels and fibrogenesis are markedly reduced in mice treated with a combination of three nonabsorbable oral antibiotics (ampicillin, neomycin sulfate, vancomycin) and metronidazole, suggesting that intestinal flora can be the main source of increased amounts of LPS, and indicating that intestinally derived endotoxins may drive fibrogenesis [89] . Strong intestinal decontaminants reduce fibrosis, angiogenesis, and portal hypertension in a mutant mice model of intravenous ligation [110] . In particular, administration of antibiotics decreases the chance of developing spontaneous hepatic bacterial peritonitis and hepatorenal syndrome [111] . Gut decontamination in mice fed an HF diet also reduces the levels of endotoxins, improves glucose tolerance, and decreases the levels of hepatic triglycerides [112] .
Initially, NASH was a frequent complication of jejunoileal bypass surgery for morbid obesity during the 1980s and could be reversed by treatment with metronidazole [113] . Although the precise mechanism of this type of NASH is not fully understood, antibiotics appear to prevent this complication. Other examples show that antibiotics can reduce hepatic steatosis and endotoxemia in an NAFLD model of rodents fed a fructose-rich diet [114] . Of note, mucosal injury can lead to hepatic damage by increased permeability of small intestine and absorption of toxic products such as bacterial cell-wall polymers; however, antibiotics reduce the absorption of peptidoglycan-polysaccharide polymers derived from bacteria, thereby preventing hepatic injury [115] . Furthermore, recruitment of migratory macrophages is significantly suppressed by treatment with antibiotics when mice receive a new class of HF diet; this suggests that gut microbiota and related metabolites are indispensable for macrophage recruitment to the liver [116] .
In accordance with these observations, a short-term treatment with 1200 mg/day rifaximin inhibits the production of endotoxins in patients with NAFLD/NASH [117] . A significant reduction in the levels of transaminases was observed in this study, although serum levels of TLR4 and IL-1, IL-6, IL-12, or TNF-α do not appear to be affected. Antibiotics decrease choline-deficient, L-amino acid-defined (CDAA)-induced liver fibrosis and HSC activation, thereby reducing intestinal permeability [118] . Membrez et al. [119] have shown that modulation of intestinal microbiota and improved glucose response in ob/ob mice is associated with altered expression of hepatic and intestinal genes involved in inflammation. These results highlight the role of flora in the small intestine, implying that treating SIBO may decrease LPS concentrations. However, antibiotics are not generally used to treat NASH. Antibiotics can result in unwanted side effects when administered long-term. Moreover, bacterial resistance may limit the efficacy of antibiotics and predispose patients to serious conditions, such as fungal and pathogenic bacteria overgrowth, with increased risk of morbidity and mortality [120] .
Association between probiotics and clinical outcomes in hepatic injury
Numerous studies have shown the positive effects of probiotics in influencing immune responses and preventing the development of HSCs from genetically obese mice with endotoxemia developed a pro-inflammatory phenotype [30] LPS-induces pro-inflammatory pattern in HSCs [64] MFB after stimulation with TNF-α are highly LPS-responsive and release large amounts of MCP-1 [151] [ Yamada et al. [116] Ceftazidime plus Metronidazole Mice were fed with a new class of HF diet Modifying the composition of the gut microbiota and related metabolic activities prevented NASH and activation of liver macrophages Douhara et al. [118] Polymyxin and neomycin Rats on CDAA diet Reduced hepatic fibrosis and HSC activation Improved intestinal permeability Seki et al. [89] Ampicillin, neomycin sulfate, metronidazole, and vancomycin BDL TLR4-mutant mice Decreased fibrosis, macrophage infiltration, and TLR4 expression Bergheim et al. [114] Polymyxin B and neomycin Mice had free access to solutions containing 30% glucose, fructose, sucrose, or water sweetened with artificial sweetener
Reduced hepatic lipid accumulation Cani et al. [112] Ampicillin and neomycin Wild type and ob/ob mice were fed a HF, carbohydrate-free diet
Reduced endotoxemia and improved glucose tolerance
Osman et al. [123] Lactobacillus plantarum and Bifidobacterium infantis with and without blueberry Acute liver injury was induced in rats with GalN and endotoxins
Reduced inflammation, improved barrier functions, and antioxidant activity
Li et al. [12] VSL#3 ob/ob controls fed an HF diet Improved liver histology and decreased levels of hepatic fatty acid, alanine aminotransferase, IR, fatty acid β-oxidation Velayudham et al.
[129]
VSL#3 MCD diet-induced mouse model of NASH Modulated liver fibrosis but did not protect from inflammation and steatosis. Upregulated serum endotoxin and expression of TLR4 signaling components, including CD14 and MD2, MyD88, NF-κB, and modulated collagen expression and impaired TGF-β signaling Esposito et al. [131] VSL#3 Rats fed a HF liquid diet (71% of energy) Reduced TNF-α levels, MMP-2 and MMP-9 activities, and expression of iNOS, COX-2, PPAR-α Modulated the NF-KB pathway Mencarelli et al.
[132] [124]
VSL#3
Mice were injected with LPS and D-GalN in the presence and absence of the PPAR gamma inhibitor GW9662
Prevented the breakdown in intestinal barrier function, reduced bacterial translocation, and attenuated liver injury with involvement of a PPAR gamma-dependent mechanism Xue et al. [126] Bifidobacterium infantis, Lactobacillus acidopilus, and Bacillus cereus HF and sucrose diet induced liver disease in a rodent model Ameliorated dysbiosis, decreased inflammatory cytokines, attenuated increased serum liver enzymes and glycometabolic biomarkers Wagnerberger et al. [134] Lactobacillus casei Shirota A mouse model of fructose-induced steatosis Attenuated the induction of TLR-4 signalling cascade, formation of ROS and expression of TNF-α. Increased activity of PPAR gamma in the liver Okubo et al. [135] Lactobacillus casei Shirota MCD diet induced NASH in a rodent model Increased the population of L. casei subgroup and of other lactic acid bacteria, suppressed NASH with reduced serum LPS levels Ritze et al. [136] Lactobacillus rhamnosus GG Experimental NAFLD was induced in mice by a HFr diet via the drinking water Improved intestinal barrier, reduced LPS levels in portal venous blood, attenuated inflammation, and inhibited steatosis Pachikian et al. [141] Dietary FOS C57Bl/6 J mice fed an n-3 PUFA-depleted diet
Reverted steatosis via stimulation of the fatty acid oxidative pathway, inhibition of the cholesterol synthesis, improvement of hepatic insulin sensitivity, and increased production of a gutderived hormone Cani et al. [146] OFS ob/ob mice Increased intestinal proglucagon mRNA, GLP-2 and modulated gut barrier function and inflammation Busserolles et al. [145] OFS Rats were fed a HFr diet Prevented TG accumulation in the liver, hyperlipemia, and lower plasma of vit E/TG Clinical studies Fernández et al. [111] Norfloxacin Patients with cirrhosis and low protein ascitic levels with advanced liver failure or impaired renal function Decreased incidence of spontaneous bacterial peritonitis, hepatorenal syndrome and increased 1-year probability of survival Drenick et al. [113] Metronidazole Patients after intestinal bypass surgery Reduction in hepatic steatosis. This improvement was evident despite concurrent progressive decreases in serum albumin levels Solga et al. [130] VSL#3 4 adult human patients with NAFLD in an open label pilot trial There were no significant differences in any of the blood assays or clinical parameters, or in reduction in hepatic steatosis Loguercio et al. [128] VSL#3 NAFLD, AC, HCV-positive patients with chronic hepatitis with or without liver cirrhosis Improved plasma levels of MDA and 4-HNE in NAFLD and AC, whereas cytokines (TNF-α, IL-6, and IL-10) were improved only in AC. Improved routine liver damage tests and plasma S-NO levels in all groups Dhiman et al. [133] VSL#3 Patients with cirrhosis Reduced the risk of hospitalization, as well as Child-Turcotte-Pugh and model for end-stage liver disease scores Aller et al. [127] Lactobacillus bulgaricus and Streptococcus thermophilus inflammatory diseases. Probiotics are live microbes that modulate intestinal microflora and increase overall health by immunoregulatory and anti-inflammatory activity; modifying permeability and epithelial function; improving intestinal barrier defense; defending against LPSinduced liver damage; exerting antioxidant activity; and improving liver-function [121] [122] [123] [124] [125] . This suggests that probiotics can improve the composition of gut microbiota, downregulate serum levels of LPS and liver TLR4, which delay the progression of liver disease [126] . Bifidobacterium and Lactobacillus are extensively used as probiotics because they efficiently reduce the growth of pathogenic microorganisms. Although these probiotics are usually present in the intestine, the population of probiotic microbes is reduced under pathogenic setting. A randomized double-blind controlled study found that in adults with NAFLD, treatment with 500 million Lactobacillus bulgaricus and Streptococcus thermophiles decreased the levels of liver transaminase [127] . VSL#3, a mixture of Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, and L. bulgaricus, showed beneficial effects in hepatic injury [128, 129] , although Solga et al. [130] found that VSL#3 negatively affected patients with hepatic steatosis. In rats with oxidative and inflammatory injury induced via administration of HF-diet, VSL#3 blocked augmented expression of inflammatory mediators in the liver [131] . VSL#3 also prevented IR, steatohepatitis, and reduced aortic plaques in a mouse model of atherogenesis, where low status of inflammation aggravates atherosclerosis [132] . Moreover, VSL#3 improved the quality of life, and decreased both Child-Turcotte-Pugh-class and Model of End-Stage Liver Disease scores, with improvement of liver function in patients with cirrhosis [133] .
In terms of NASH severity, administering probiotics to leptin-deficient ob/ob mice considerably decreases hepatic lipid accumulation by counteracting anti-TNF antibodies; this suggests a relationship between the enteric flora and liver injury [12] . In mouse model, Lactobacillus casei Shirota exerted positive effects on fructose-induced liver injury by regulating the expression of TLR4 [134] , and suppressed serum LPS concentrations, reducing inflammation, and protecting against hepatic steatosis and fibrosis in liver of a MCD diet [135] . Nevertheless, few studies have investigated whether administration of probiotics can decrease hepatic fibrosis in human patients, and the majority of studies have focused on treating complications in advanced stages of the illness. In this phase, liver fibrosis is irreversible due to development of collagen crosslinks; as a result, any beneficial effects of probiotics at this stage of fibrosis would be highly improbable. Hence, while recent investigations with numerous strains of probiotics, including Lactobacillus rhamnosus, Lactobacillus plantarum bulgaricus, and Lactobacillus casei showed positive effects in rodent models [134] [135] [136] [137] , randomized clinical trial data collected long-term are not presently available.
Treatment with prebiotics and alterations in gut microbiota, inflammation, steatosis, and plasma levels of gut peptides
Prebiotics are indigestible carbohydrates that favorably affect the expansion and activity of gut bacteria, mainly those of Bifidobacteria and Lactobacilli [138] . Although studies show that prebiotics can potentially be used as a nutritional treatment for patients with NAFLD/ NASH, high-quality clinical trials on this subject are currently lacking.
The prebiotic oligofructose (OFS) is a nondigestible oligomer of β-Dfructose, acquired by enzymatic hydrolysis of inulin or oligofructose removed from chicory root [139] . OFS is readily fermented in the colon, triggering selective production of Bifidobacterium [140] . In mice that are administered a polyunsaturated fatty acid-depleted diet to induce hepatic steatosis, OFS protects against steatosis, which is accompanied by decreased oxidation of fatty acids [141] . In patients with NASH, property of B. longum and the synthetic fructooligosaccharides (FOS) associated with lifestyle alteration versus lifestyle alteration only included metabolic and anti-inflammatory effects [142] . Daubioul et al. [143] reported improved activity of hepatic enzymes in patients with NASH receiving dietary fructans. Ferolla et al. [144] observed a reduction in steatosis, body weight, body mass index (BMI), waist circumference, and uric acid levels in patients with NASH administered guar gum and inulin (1 × 108 CFU of L. reuteri) twice daily for 3 months; however, no effects on gut permeability or SIBO were observed.
Products of butyrate fermentation are energetic substrates for colonocytes. In this metabolic cascade, trophic influences on mucosa can increase the ratio of propionate to acetate in rats administered high fructose (HFr) diet [145] ; this can reduce lipogenesis because propionate decreases lipogenesis while acetate stimulates it. These data show that in carbohydrate fermentation, administration of HFr diet decreases the levels of pooled SCFA, but, supplementation with OFS affects fructose absorption. Especially, prebiotics can influence the production of the gut trophic hormone, glucagon-like peptide-2, which modulates lipid and LPS absorption via its effects on intestinal permeability [146] . This may positively impact the integrity of gut barrier.
Conclusions and perspectives
Studies indicate that gut microbiota play a central role in the fibrotic processes of NAFLD, and increased levels of endotoxins have been found to exacerbate NASH evolution. However, the complexity of NAFLD/NASH, as well as differences between individuals, renders it difficult to conduct population studies. There is no effective treatment for NASH, and the efficacy of new therapeutic approaches has not been assessed in human patients due variations in methodology, and dietary that may lead to different fibro-inflammatory phenotypes. Indeed, persistent exposure to gut-derived bacterial endotoxins may contribute to hepatic hemodynamic regulation and immune responses. Nevertheless, the connections between metabolic pathways of the gut microbial system and the immune system have not yet been well delineated. Further studies are needed to address whether the course of NASH can be altered by modulating the gut microbiota. Determining exactly how the gut microbiome participates in NASH will certainly advance our knowledge and development of treatment options.
Declarations of interest
None.
